NewsFDASaturday, August 30, 2025 · August 30, 2025
PNH Patients Gain Subcutaneous Complement Inhibitor
WHY IT MATTERS
Home-based treatment reduces hospital visits for PNH patients.
New subcutaneous complement C5 inhibitor approved for PNH, offering self-administered alternative.
Related conditions
Related news
FDA
FDA Approves XTORO
XTORO (FINAFLOXACIN) received FDA approval.…
FDA
FDA Approves IOPIDINE
IOPIDINE (APRACLONIDINE HYDROCHLORIDE) received FDA approval.…
FDA
FDA Approves SABRIL
SABRIL (VIGABATRIN) received FDA approval.…
FDA
FDA Approves IOPIDINE
IOPIDINE (APRACLONIDINE HYDROCHLORIDE) received FDA approval.…